Literature DB >> 16961550

Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version.

Alison Woodcock1, Clare Bradley.   

Abstract

OBJECTIVES: Previous validation of the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs) found that nine of the 10 items performed well, but the demands item needed revision. This study investigated the psychometric properties of the revised HIVTSQs and new change version (HIVTSQc).
METHODS: English-speaking Americans completed the HIVTSQs at baseline and Week 48 of a clinical trial of HIV treatments, and the HIVTSQc at Week 48. Demographic and viral load information was collected. Psychometric validation used item frequency distributions, Confirmatory Factor Analysis (CFA), item-total correlations, Cronbach's alpha, Spearman's rank correlation, Kruskal-Wallis and Mann-Whitney tests.
RESULTS: At baseline, 126 of the 152 patients completed the HIVTSQs fully (100 of 106 at Week 48). The negatively skewed distribution of the revised demands item resembled that of the other nine, with comparable missing data. CFA (baseline and Week 48) supported the general satisfaction/clinical subscale (alpha 0.83; 0.85), lifestyle/ease subscale including demands (alpha 0.82; 0.85), and 10-item treatment satisfaction scale (alpha 0.89; 0.91). Subscale and scale scores differed significantly between ethnic groups. Viral load was not significantly related to subscale or scale scores. At Week 48, 97 of 106 patients completed the HIVTSQc fully. All items had negatively skewed distributions. CFA supported two subscales (general satisfaction/clinical change alpha 0.85; lifestyle/ease change alpha 0.88) and 10-item treatment satisfaction change scale (alpha 0.92). Viral load change between baseline and Week 48 correlated significantly with patients' perceptions of change in HIV control (control(c) item), but not with scale or subscale scores.
CONCLUSION: The excellent psychometric properties of the HIVTSQs and HIVTSQc support their use in clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16961550     DOI: 10.1111/j.1524-4733.2006.00121.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  12 in total

1.  Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

Authors:  Elizabeth C George; Raffaella Bucciardini; Laura Richert; Nikos Dedes; Vincenzo Fragola; Pythia Nieuwkerk; Bruno Spire; Alain Volny-Anne; Brian West; Jean-Michel Molina; Andrzej Horban; Julie Fox; Anton Pozniak; Stefano Vella; Monique Termote; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

2.  Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine.

Authors:  Chenglin Hong; Nancy Puttkammer; Serhii Riabokon; Myroslava Germanovich; Alyona Shost; Canada Parrish; Anna Shapoval; Kostyantyn Dumchev
Journal:  AIDS Behav       Date:  2021-09-13

Review 3.  Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.

Authors:  Mario Cruciani; Marina Malena
Journal:  Patient Prefer Adherence       Date:  2015-02-17       Impact factor: 2.711

4.  Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.

Authors:  Anthony Mills; Will Garner; Anton Pozniak; Juan Berenguer; Rebecca M Speck; Randall Bender; Thai Nguyen
Journal:  Patient       Date:  2015-08       Impact factor: 3.883

5.  Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.

Authors:  Jason Brunetta; Santiago Moreno Guillén; Andrea Antinori; Patrick Yeni; Barbara Wade; Margaret Johnson; Peter Shalit; Ramin Ebrahimi; Bethsheba Johnson; Ivan Walker; Shampa De-Oertel
Journal:  Patient       Date:  2015-06       Impact factor: 3.883

6.  Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential.

Authors:  Cristina Fernandez; Clare L van Halsema
Journal:  HIV AIDS (Auckl)       Date:  2019-07-31

7.  Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.

Authors:  Gregory D Huhn; Gordon Crofoot; Moti Ramgopal; Joseph Gathe; Robert Bolan; Donghan Luo; Richard Bruce Simonson; Richard E Nettles; Carmela Benson; Keith Dunn
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

8.  Patient satisfaction with HIV/AIDS care and treatment in the decentralization of services delivery in Vietnam.

Authors:  Bach Xuan Tran; Nhung Phuong Thi Nguyen
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

9.  Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.

Authors:  Joseph Gathe; Jose R Arribas; Jan Van Lunzen; Will Garner; Rebecca M Speck; Randall Bender; Sanatan Shreay; Thai Nguyen
Journal:  Patient       Date:  2015-10       Impact factor: 3.883

10.  Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.

Authors:  Andrea Antinori; Maria V Cossu; Barbara Menzaghi; Gaetana Sterrantino; Nicola Squillace; Valentina Di Cristo; Annamaria Cattelan; Emanuele Focà; Antonella Castagna; Giancarlo Orofino; Daniela Valenti; Gabriella D'Ettore; Lucia Aprea; Sergio Ferrara; Maria E Locatelli; Giordano Madeddu; Emanuele Pontali; Paolo Scerbo; Barbara Rossetti; Alessia Uglietti; Roberta Termini; Francesco Rucci; Andrea Gori; Daniela Mancusi
Journal:  Patient       Date:  2020-06       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.